Ashland reports fourth quarter and full-year fiscal 2026 results and issues outlook for fiscal 2027
Key Highlights
- ➤Q4 sales $498 million, up four percent year over year
- ➤Q4 adjusted EPS $1.12, up from $1.08 year over year
- ➤Q4 Adjusted EBITDA $121 million, up two percent year over year
- ➤Fiscal 2026 Adjusted EBITDA $385 million, down from $401 million
- ➤Fiscal 2027 guidance: sales $1,905-$1,975 million, Adjusted EBITDA $405-$435 million
Expert Statements
Guillermo Novo, Chair and chief executive officer, Ashland
“Ashland closed fiscal 2026 with strong commercial performance across our higher-growth Life Sciences and Personal Care businesses, as well as coatings and performance specialties within Specialty Additives, and improved profitability in Intermediates.”
Guillermo Novo, Chair and chief executive officer, Ashland
“Life Sciences delivered four percent sales growth, and pharma achieved its sixth consecutive quarter of year-over-year volume growth, with broad gains across regions and continued momentum from our globalize and innovate strategies. Personal Care generated another quarter of strong performance, with eight percent sales growth, including double-digit growth in biofunctional actives, microbial protection and hair care, and high-single-digit growth in skin care. Specialty Additives delivered nine percent sales growth in coatings and fourteen percent sales growth in performance specialties, reflecting share gains across all regions. These gains were offset by soft end-market demand in energy and resources and lower construction volumes resulting from deliberate portfolio actions.”
Guillermo Novo, Chair and chief executive officer, Ashland
“Our globalize and innovate strategies exceeded their full-year targets, driven by deep customer engagement and successful commercialization. Despite raw material and freight volatility, our teams executed well, with pricing actions recovering higher raw material costs. We have completed the critical investments needed to support improved productivity at our plants. We also generated healthy cash flow, further strengthening our financial flexibility as we enter fiscal 2027.”
Guillermo Novo, Chair and chief executive officer, Ashland
“Our priorities are clear: improve operating performance, drive productivity across our network, maintain pricing discipline, build on our commercial momentum and continue to scale our globalize and innovate initiatives. The strategic foundations are in place, and our focus is on execution to deliver improved profitability and long-term value creation.”
* Sales of $498 million, up four percent from the prior-year quarter * Loss from continuing operations of $17 million, or ($0.36) per diluted share * Adjusted Income from Continuing Operations Excluding Intangibles Amortization Expense of $52 million, or $1.12 per diluted share * Net loss of $16 million, or ($0.35) per diluted share * Sales volumes rose three percent from the prior-year quarter, led by growth in Life Sciences and Personal Care * Adjusted EBITDA of $121 million, up two percent from the prior-year quarter; strong growth in Life Sciences, Personal Care, and Intermediates was partially offset by lower earnings in Specialty Additives * Cash flows provided by operating activities of $90 million; Ongoing Free Cash Flow(2) of $74 million * Issues outlook for full‑year fiscal 2027 sales of $1,905-$1,975 million and Adjusted EBITDA of $405-$435 million WILMINGTON, Del., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) today announced financial results(1) for the fourth quarter of fiscal year 2026, which ended September 30, 2026, together with its fiscal year 2026 results summary and full-year fiscal 2027 outlook. Ashland, a global additives and specialty ingredients company, holds leadership positions in high-quality, consumer-focused markets including pharmaceuticals, personal care and architectural coatings.
Get started
Create a free account to read the full story.